Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P120003/S011

iCast Covered Stent System

Atrium Medical Corp. · Decision date Sep 12, 2025

FDA DECISIONP120003/S011

What did the FDA decide?

FDA records P120003/S011 as a supplement to PMA P120003, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Sep 12, 2025.

FDA approval order statement

to add an alternate testing supplier for lot release bacterial endotoxin testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 12, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P120003/S011
Regulatory pathway
PMA supplement
Product code
PRL
Decision code
OK30
Decision date
Sep 12, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Iliac covered stent, arterial.

Product code
PRL
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P120003/S011 received

    Application receipt date recorded by FDA.

  2. P120003/S010 · Related supplement

    iCast Covered Stent System

  3. P120003/S011 · FDA decision

    30-Day Notice

  4. P120003/S009 · Related supplement

    iCast Covered Stent System

  5. P120003/S007 · Related supplement

    iCast Covered Stent System

Timeline entries are records held by MedtechLedger for P120003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P120003

Product / regulatory recordCompanyPathwayDecision dateSource
Atrium Medical Corp.PMA supplementAug 20, 2025FDA
Atrium Medical Corp.PMA supplementDec 22, 2025FDA
Atrium Medical Corp.PMA supplementMay 13, 2026FDA

Explore the linked device profile

Other records with product code PRL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Atrium Medical Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5 Wentworth Dr., Hudson, NH, 03051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records